Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Instagram Outage Disrupts Thousands of U.S. Users 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SAN FRANCISCO, Oct. 25, 2016 -- Hagens Berman Sobol Shapiro LLP reminds investors in Alnylam Pharmaceuticals, Inc. that the firm is investigating possible securities law violations by the Company and its officers.
If you purchased or otherwise acquired securities of ALNY before October 6, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/ALNY
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On October 5, 2016 Alnylam filed its Form 8-K with the SEC publicly announcing it would discontinue testing of one of its key drugs, Revusiran, “upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC).” TheStreet reported on October 6, 2016 that “[w]hen independent monitors peeked into the study results, they found 18 patients had died, more treated with revusiran than with a placebo, although how many more Alnylam won’t disclose.”
This news drove the price of Alnylam shares down over 45% during intra-day trading on October 6, 2016.
“We’re looking into when the deaths occurred relative to management’s statements about the drug’s development,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Alnylam should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
